Navigation Links
DiObex Begins Dosing Patients in Phase 2b Trial of Type 2 Diabetes Drug
Date:9/26/2007

Multinational Trial to Evaluate Safety, Efficacy of Novel Cortisol

Inhibitor

SAN FRANCISCO, Sept. 26 /PRNewswire/ -- DiObex, Inc., a privately held biotechnology company focused on the development of therapeutics to treat metabolic diseases, announced today that it has begun dosing patients in a Phase 2b clinical trial of DIO-902, a novel cortisol synthesis inhibitor being studied for the treatment of type 2 diabetes mellitus (T2DM).

The Phase 2b multinational trial is a randomized, placebo-controlled, double-blinded study designed to evaluate the safety and efficacy of DIO-902 and to determine dosing for pivotal Phase 3 clinical studies. The primary efficacy endpoint being evaluated is the change in HbA1c, a key measurement of glycemic control, compared to placebo. Secondary endpoints include the change in total and LDL-cholesterol, and the change in blood pressure. Top line data from the trial is expected by the second half of 2008.

"The rollout of this multinational, multicenter trial demonstrates DiObex's ability to launch a major clinical program for the treatment of metabolic disease," CEO David Cory said. "With treatments for both type 1 and type 2 diabetes in mid-stage clinical study and additional indications under evaluation for DIO-902, DiObex is well positioned to move a strong pipeline of product candidates into the advanced stages of development."

The trial is being conducted at 20 centers across the United States, Australia and New Zealand. Approximately 200 patients will be treated for 16 weeks. Patients who are already on a stable dose of metformin will be randomized to receive placebo or one of three doses of DIO-902 once daily for 16 weeks, with the option of continuing on an open label extension for an additional six months of treatment.

Preclinical and clinical studies have suggested that a link exists between high cortisol levels and visceral adiposity, insulin resistance, and hyperglycemia -- common elements of T2DM and metabolic syndrome. There are no cortisol synthesis inhibitors on the market today, potentially making DIO-902 a first-in-category treatment.

"We are very encouraged by results of our earlier Phase 2a study that showed a trend toward improved glycemic control, as well as statistically significant reductions in levels of cholesterol and C-reactive protein that suggest DIO-902 could potentially lower the risk of heart disease," said Dr. Bernice Welles, Vice President of Development at DiObex. "DIO-902 could potentially give patients a way to manage their disease with fewer medications and, if ultimately approved, would be a valuable addition to the armamentarium of agents to help patients with type 2 diabetes."

About DIO-902

DIO-902 is a cortisol synthesis inhibitor that is being developed as a therapy for glucose and cholesterol control in patients with T2DM. DIO-902 may also benefit hypercholesterolemia patients who fail to achieve treatment targets on current lipid medications or those who are statin intolerant. DIO-902 increases insulin sensitivity by lowering cortisol levels. The primary mechanism of action is via inhibition of the 11-beta-hydroxylase

enzyme, the terminal step in cortisol synthesis in the adrenal gland. DIO-902 has also been shown to lower total and LDL-cholesterol by inhibiting 14-alpha-demethylase, a key enzyme in cholesterol synthesis. DIO-902 is the levdex enantiomer of ketoconazole. Pre-clinical and clinical evidence are supportive that DIO-902 may be safer and more effective than racemic ketoconazole.

About DiObex

DiObex, Inc. is a San Francisco-based biotechnology company founded to develop novel products for the treatment of metabolic diseases. DiObex has two product candidates in Phase 2 clinical development. DIO-901 (very low dose glucagon) is in development as an extended release subcutaneous formulation for reducing or preventing insulin-induced hypoglycemia in type 1 diabetes mellitus. DIO-901 has received Fast Track status from the Food and Drug Administration. DIO-902 (levdexketoconazole) is a novel cortisol synthesis inhibitor in development for T2DM. Abnormalities in cortisol activity may play an important role in the development of metabolic syndrome, a constellation of conditions that place people at high risk for T2DM and cardiovascular disease. For more information, visit http://www.diobex.com.


'/>"/>
SOURCE DiObex, Inc.
Copyright©2007 PR Newswire.
All rights reserved

Related medicine technology :

1. DiObex Presents Phase 2a Data of DIO-902 Demonstrating Trends of Improved Glycemic Control and Significant Reductions of LDL-Cholesterol and C-Reactive Protein
2. Diobex Announces Successful Completion of Phase 2a Trial Of DIO-902, a Novel Cortisol Synthesis Inhibitor for Type 2 Diabetes
3. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
4. Phase II Results Show Once-Daily Dosing of Human GLP-1 Analog Liraglutide, Brings Patients to A1c Target
5. New Study Shows A1c Reduced Safely By Patients With Type 2 Diabetes Using Self-Adjusted Dosing Starting With Once-Daily Insulin Treatment Levemir
6. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
7. ChemGenex Reports Successful Personalized Dosing of Quinamed at ASCO
8. Celator Pharmaceuticals Study Shows Anti-Tumor Activity in Cancer Patients Treated with Therapy Based on Ratiometric Dosing
9. PC-DAC:Exendin-4 Phase I/II Multiple-Dose Study Preliminary Results Demonstrate Safety and Efficacy at Once-Weekly Dosing
10. Sunesis Pharmaceuticals Presents SNS-314 Aurora Kinase Inhibitor Data Showing Broad Anti-Tumor Activity, Dosing Flexibility
11. Active Biotechs I-3D Micro-dosing Clinical Trial Concluded
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/5/2016)... 5, 2016  Zimmer Biomet Holdings, Inc. (NYSE and ... announced underwritten secondary offering of 11,027,558 shares of its ... affiliates of Blackstone and Goldman Sachs.  The shares are ... of $96.45 per share. The selling stockholders will receive ... Biomet nor any of its directors, officers or other ...
(Date:2/5/2016)... 2016 Site Profile: --> ... - The Speech Recognition People, announced their latest primary healthcare case ... care, reduce turnaround times and to save the practice money. ... since 2013 Challenge: --> ,- Wirral CCG ... - Six doctors ,- Wirral CCG ,- VoicePower client since 2013 ...
(Date:2/4/2016)... For hospitals considering enrollment in the Federal ... the program, the Health Resources and Services Administration,s (HRSA) ... Mega-Guidance , could have significant impact on plans and ... 2016. Essential Insights , Daniel Neal, ... the Mega-Guidance,s key proposed changes, including a new requirement ...
Breaking Medicine Technology:
(Date:2/5/2016)... UT (PRWEB) , ... February 05, 2016 , ... Today, ... Nutrition , announced that the much-anticipated feature with author Jahnavi Foster, specialist in healthy ... Amateur TV Network. , Each week, on his weekly Whole-Food Warrior TV show, Frank ...
(Date:2/5/2016)... MN (PRWEB) , ... February 05, 2016 , ... The ... at the Day Block Event Center in Minneapolis, Minn. Triumph Over Parkinson’s will fund ... Larry Schneiderman, owner of Schneiderman’s Furniture, lives with Parkinson’s disease and is the architect ...
(Date:2/5/2016)... ... February 05, 2016 , ... Francisco Canales, MD and Heather ... Napa Valley office. The technique utilizes the body’s own healing abilities to quickly ... Furnas, are part of only a select few cosmetic surgeons bringing this procedure ...
(Date:2/5/2016)... ... February 05, 2016 , ... Freed-Hardeman University President Joe A. ... a joint enrollment and degree completion agreement. The agreement, which begins with ... at FHU|Dickson. , The agreement allows students to be jointly admitted to ...
(Date:2/5/2016)... ... February 05, 2016 , ... The Lymphoma Research Foundation (LRF) ... and serving the lymphoma community through a comprehensive series of education programs, outreach ... Wine Tasting Event at the La Gorce Country Club in Miami Beach on ...
Breaking Medicine News(10 mins):